Edgewise Therapeutics Shares Are Trading Higher After JP Morgan Maintained an Overweight Rating and Raised the Price Target From $27 to $30.
Edgewise Therapeutics Shares Are Trading Higher After JP Morgan Maintained an Overweight Rating and Raised the Price Target From $27 to $30.
JP Morgan 維持 Edgewise Therapeutics 股票超配評級並將目標價格從 27 美元提高至 30 美元后，股票在交易中走高。
Edgewise Therapeutics Shares Are Trading Higher After JP Morgan Maintained an Overweight Rating and Raised the Price Target From $27 to $30.
JP Morgan 維持 Edgewise Therapeutics 股票超配評級並將目標價格從 27 美元提高至 30 美元后，股票在交易中走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。